MedCodeSearch
HCPCS Level II Current in October 2026

G2207

Reason for not administering adjuvant treatment course including both chemotherapy and her2-targeted therapy (e.g. poor performance status (ecog 3-4; karnofsky <=50), cardiac contraindications, insufficient renal function, insufficient hepatic function, other active or secondary cancer diagnoses, other medical contraindications, patients who died during initial treatment course or transferred during or after initial treatment course)

Release
October 2026
Effective
Official source (opens in a new tab)

Version History

How G2207 appears in each release imported from the official files, newest first.

  1. October 2026 Effective

    Current

    Reason for not administering adjuvant treatment course including both chemotherapy and her2-targeted therapy (e.g. poor performance status (ecog 3-4; karnofsky <=50), cardiac contraindications, insufficient renal function, insufficient hepatic function, other active or secondary cancer diagnoses, other medical contraindications, patients who died during initial treatment course or transferred during or after initial treatment course)

  2. July 2026 Effective

    Unchanged

    Reason for not administering adjuvant treatment course including both chemotherapy and her2-targeted therapy (e.g. poor performance status (ecog 3-4; karnofsky <=50), cardiac contraindications, insufficient renal function, insufficient hepatic function, other active or secondary cancer diagnoses, other medical contraindications, patients who died during initial treatment course or transferred during or after initial treatment course)

  3. April 2026 Effective

    Unchanged

    Reason for not administering adjuvant treatment course including both chemotherapy and her2-targeted therapy (e.g. poor performance status (ecog 3-4; karnofsky <=50), cardiac contraindications, insufficient renal function, insufficient hepatic function, other active or secondary cancer diagnoses, other medical contraindications, patients who died during initial treatment course or transferred during or after initial treatment course)

  4. January 2026 Effective

    Unchanged

    Reason for not administering adjuvant treatment course including both chemotherapy and her2-targeted therapy (e.g. poor performance status (ecog 3-4; karnofsky <=50), cardiac contraindications, insufficient renal function, insufficient hepatic function, other active or secondary cancer diagnoses, other medical contraindications, patients who died during initial treatment course or transferred during or after initial treatment course)

Data Source

Code information on this page is derived from the October 2026 HCPCS Level II files published by CMS.

Release
October 2026
Effective
Source file
october-2026-alpha-numeric-hcpcs-file.zip

Official HCPCS Level II source files (opens in a new tab)

MedCodeSearch is an independent reference service and is not affiliated with CMS, CDC, or the U.S. government.

Look up another code

Search ICD-10-CM, ICD-10-PCS and HCPCS Level II by code or description.